NextCube

NextCube is a South Korean biotechnology company focused on developing first-in-class small molecule therapeutics for cancer and fibrotic diseases. The company leverages its proprietary CUBE (Computational Understanding of Biological Entities) platform, which combines structural biology and computational modeling to target challenging protein-protein interactions. Its lead program, NC-101, is a potent inhibitor of the DNA repair protein RAD51, aimed at treating various solid tumors by overcoming chemoresistance. NextCube is also advancing NC-201, a candidate targeting idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis. By focusing on 'undruggable' targets, the company seeks to provide innovative solutions for patients with limited treatment options.